专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US4994259A Improvement in the method of NMR imaging employing a manganese II chelates of N,N'-bis[pyridoxal-alkylene (or cycloalkylene) (or arylene)]-N,N'-diacetic acid derivatives 失效
标题翻译：使用N，N'-双[吡哆醛 - 亚烷基（或亚环烷基）（或亚芳基）] -N，N'-二乙酸衍生物的锰II螯合物的NMR成像方法的改进
公开(公告)号：US4994259A
公开(公告)日：1991-02-19
申请号：US380185
申请日：1989-07-14
申请人： Scott M. Rocklage , Steven C. Quay
发明人： Scott M. Rocklage , Steven C. Quay
IPC分类号： A61K49/06 , C07D213/66 , C07F13/00
CPC分类号： C07D213/66 , A61K49/06 , C07F13/005 , Y10T436/145555 , Y10T436/24
摘要： Manganese(II) chelates of N,N'-bis-(pyridoxal)-alkylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-1,2-cycloalkylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-1,2-arylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-alkylenediamine-N-acetic acids, N,N'-bis-(pyridoxal)-1,2-cycloalkylenediamine-N-acetic acids, N,N'-bis-(pyridoxal)-1,2-arylenediamine-N-acetic acids, and their salts are highly stable, superior NMRI contrast agents. They maintain the manganese(II) ion in the +2 valence state. Preferred contrast agents are manganese(II) ion chelates of N,N'-bis-(pyridoxal)ethylenediamine-N,N'-diacetic acid, N,N'-bis-(pyridoxal)trans-1,2-cyclohexylenediamine-N,N'-diacetic acid, and the salts and esters thereof.Novel chelate forming compounds are the N,N'-bis-(pyridoxal)-1,2-cycloalkylenediamine-N,N'-diacetic acids and N,N'-bis-(pyridoxal)1,2-arylene-diamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-alkylenediamine-N-acetic acids, N,N'-bis(pyridoxal)-1,2-cycloalkylenediamine-N-acetic acids, N,N'-bis-(pyridoxal)-1,2-arylenediamine-N-acetic acids, and their salts and esters.
摘要翻译： N，N'-双 - （吡哆醛） - 亚烷基二胺-N，N'-二乙酸，N，N'-双 - （吡哆醛）-1,2-环烷二胺-N，N'-二乙酸的锰（II）螯合物酸，N，N'-双 - （吡哆醛）-1,2-芳基二胺-N，N'-二乙酸，N，N'-双 - （吡哆醛） - 亚烷基二胺-N-乙酸，N，双（吡哆醛）-1,2-环亚烷基二胺-N-乙酸N，N'-双 - （吡哆醛）-1,2-芳基二胺-N-乙酸及其盐是高度稳定的，优良的NMRI造影剂。它们保持+2价态的锰（II）离子。优选的造影剂是N，N'-双 - （吡哆醛）乙二胺-N，N'-二乙酸，N，N'-双 - （吡哆醛）反-1,2-环己二胺-N ，N'-二乙酸及其盐和酯。新型螯合形成化合物是N，N'-双 - （吡哆醛）-1,2-环烷二胺-N，N'-二乙酸和N，N'-双（吡哆醛）1,2-亚芳基二胺-N N，N'-二 - （吡哆醛） - 亚烷基二胺-N-乙酸，N，N'-双（吡哆醛）-1,2-环烷二胺-N-乙酸，N，N' 双 - （吡哆醛）-1,2-芳基二胺-N-乙酸及其盐和酯。

62. 发明授权

US4935518A Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof 失效
标题翻译：锰（II），衍生自N，N'-双 - （吡哆醛乙二胺-N，N'） - 二乙酸及其衍生物的螯合造影剂
公开(公告)号：US4935518A
公开(公告)日：1990-06-19
申请号：US047584
申请日：1987-05-08
申请人： Scott M. Rocklage , Steven C. Quay
发明人： Scott M. Rocklage , Steven C. Quay
IPC分类号： A61K49/00 , A61K49/06 , C07D213/66 , C07F13/00
CPC分类号： C07D213/66 , A61K49/06 , C07F13/005 , Y10T436/24
摘要： Managanese(II) chelates of N,N'-bis-(pyridoxal)-alkylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-1,2-cycloalkylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-1,2-arylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-alkylenediamine-N-acetic acids, N,N'-bis-(pyridoxal)-1,2-cycloalkylenediamine-N-acetic acids, N,N'-bis-(pyridoxal)-1,2-arylenediamine-N-acetic acids, and their salts are highly stable, superior NMRI contrast agents. They maintain the manganese(II) ion in the +2 valence state. Preferred contrast agents are manganese(II) ion chelates of N,N'-bis-(pyridoxal)ethylenediamine- N,N'-diacetic acid, N,N'-bis-(pyridoxal)trans-1,2-cyclohexylenediamine-N,N'-diacetic acid, and the salts and esters thereof.Novel chelate forming compounds are the N,N'-bis-(pyridoxal)-1,2-cycloalkylenediamine-N,N'-diacetic acids and N,N'-bis-(pyridoxal)-1,2,-arylenediamine-N,N'-diacetic acids, N,N'-bis-(pyridoxal)-alkylenediamine-N-acetic acids, N,N'-bis(pyridoxal)-1,2-cycloalkylenediamine-N-acetic acids, N,N'-bis-(pyridoxal)-1,2-arylenediamine-N-acetic acids, and their salts and esters.

63. 发明授权

US4863716A Determination of fallopian tubal patency by magnetic resonance imaging 失效
标题翻译：通过磁共振成像确定输卵管输卵管通畅
公开(公告)号：US4863716A
公开(公告)日：1989-09-05
申请号：US58180
申请日：1987-06-04
申请人： Steven C. Quay , Scott M. Rocklage
发明人： Steven C. Quay , Scott M. Rocklage
IPC分类号： A61K49/06 , C07F9/58 , C07F13/00 , G01R33/28
CPC分类号： G01R33/5601 , A61K49/06 , C07F13/005 , C07F9/582 , Y10S436/806 , Y10T436/24
摘要： This invention is a method for obtaining improved NMR images of the uterine cavity and fallopian tubes comprising imjecting a physiologically acceptable solution of a chelate of a parmagnetic material into the uterus under sufficient pressure to cause the solution to pass through the fallopian tubes and obtaining an enhanced NMR image of the tissue surrounding the fallopian tubes. The chelates and the injection solutions thereof do not include carbohydrate groups or other compounds which might support growth of Staphylococcus aureus or other pathological miroorganisms in the peritoneal cavity.Kits including contrast medium and non-metallic uterine balloon catheters suitable for use with NMRI procedures are also included within the scope of this invention.
摘要翻译：本发明是一种用于获得子宫腔和输卵管的改进的NMR图像的方法，包括在足够的压力下将对数磁性材料的螯合物的生理上可接受的溶液注入到子宫中，以使溶液通过输卵管并获得增强的围绕输卵管的组织的NMR图像。螯合物及其注射溶液不包括碳水化合物基团或可能支持金黄色葡萄球菌生长或其它病理性微生物在腹膜腔中的其他化合物。适用于NMRI方法的造影剂和非金属子宫气囊导管的试剂盒也包括在本发明的范围内。

64. 发明授权

US4859451A Paramagnetic contrast agents for MR imaging 失效
标题翻译：顺磁造影剂用于MR成像
公开(公告)号：US4859451A
公开(公告)日：1989-08-22
申请号：US855223
申请日：1986-04-24
申请人： Steven C. Quay , Dilip M. Worah
发明人： Steven C. Quay , Dilip M. Worah
IPC分类号： A61K49/06 , G01N33/00 , G01R33/28
CPC分类号： G01R33/5601 , A61K49/06 , Y10S436/806 , Y10T436/24
摘要： In the NMR imaging of a subject comprising administering to such subject a composition containing an image-modifying effective amount of an image enhancer, permitting the enhancer to move through the subject, and after a time interval taking an NMR image of the subject, the improvement which comprises employing as said enhancer a complex of a paramagnetic polyvalent metal and a partial amide and/or ester of diethylenetriaminepentaacetic acid. The complexes are new.
摘要翻译：在受试者的NMR成像中，包括向所述受试者施用含有图像改善有效量的图像增强子的组合物，允许增强剂移动通过受试者，并且在经受时间间隔取对象的NMR图像之后，改善其包括使用顺磁性多价金属和二亚乙基三胺五乙酸的部分酰胺和/或酯的络合物作为所述增强剂。复合体是新的。

65. 发明授权

US09074205B2 Nicked or gapped nucleic acid molecules and uses thereof 有权
标题翻译：有缺陷或间隙的核酸分子及其用途
公开(公告)号：US09074205B2
公开(公告)日：2015-07-07
申请号：US12445868
申请日：2007-10-18
申请人： Steven C. Quay , James Mcswiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James Mcswiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C07H21/02 , C07H21/04 , A61K48/00 , C12N15/11 , A61K38/00
CPC分类号： A61K31/713 , A61K38/00 , A61K47/645 , A61K47/66 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/15 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3513 , C12N2310/533 , C12N2320/30 , C12N2320/51 , C12N2330/30 , C12N2310/3521
摘要： The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.
摘要翻译：本公开提供降低或沉默靶基因表达的meroduplex（切口或间隙）核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其组合形成由切口或间隙分开的至少两个非重叠的双链区域，其中一条链与靶基因RNA互补。此外，meroduplex可以具有一个或多个修饰或取代，例如核苷酸碱基，糖，末端帽结构，核苷酸间连键或这些修饰的任何组合。还提供减少细胞或受试者中靶基因表达以治疗与靶基因表达改变相关的疾病的方法。

66. 发明申请

US20130149378A1 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof 审中-公开
标题翻译：第二代脂肪酸组合物，制剂及其使用和合成方法
公开(公告)号：US20130149378A1
公开(公告)日：2013-06-13
申请号：US13761243
申请日：2013-02-07
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61K31/164 , A61K31/353
CPC分类号： A61K31/202 , A23L33/12 , A61K9/0053 , A61K9/145 , A61K9/146 , A61K9/4858 , A61K9/4866 , A61K31/16 , A61K31/164 , A61K31/353 , A61K31/355
摘要： An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.
摘要翻译：提供了用于治疗心血管疾病的口服给药脂肪酸组合物及其治疗方法。该化合物包括5Z，8Z，11Z，14Z，17Z-二十碳五烯酸乙醇酰胺（EPA乙醇酰胺），4Z，7Z，10Z，13Z，16Z，19Z-二十二碳六烯酸乙醇酰胺（DHA乙醇酰胺）和至少一种生育三烯酚。 EPA乙醇酰胺和DHA乙醇酰胺优选地每个剂型基本上在100-900mg的范围内。至少一种生育三烯酚基本上在每种剂型10-500mg的范围内。至少一种生育三烯酚包括α-生育三烯酚，β-生育三烯酚，γ-生育三烯酚或δ-生育三烯酚中的至少一种，并且优选基本上不含生育酚。组合物可以采取医疗食品或药物制剂的形式。组合物的优选制剂包括约525mg EPA乙醇酰胺，约315mg DHA乙醇酰胺和约50mgδ-生育三烯酚。 EPA和DHA乙醇酰胺可以由脂肪酸甘油三酯合成。

67. 发明授权

US07939505B2 Amino acid lipids and uses thereof 有权
公开(公告)号：US07939505B2
公开(公告)日：2011-05-10
申请号：US12114284
申请日：2008-05-02
申请人： Steven C. Quay , Michael Houston, Jr. , Pierrot Harvie , Roger C. Adami , Renata Fam , Mary Gallagher Prieve , Kathy Lynn Fosnaugh , Shaguna Seth
发明人： Steven C. Quay , Michael Houston, Jr. , Pierrot Harvie , Roger C. Adami , Renata Fam , Mary Gallagher Prieve , Kathy Lynn Fosnaugh , Shaguna Seth
IPC分类号： A61K47/14 , A61K47/18 , A61K48/00 , C07C279/14
CPC分类号： A61K47/183 , A61K9/127 , A61K9/1271 , A61K9/1272 , A61K31/7088 , A61K47/18 , A61K47/22 , A61K47/28 , A61K47/44 , A61K48/0025 , A61K48/0033 , C07C235/02 , C07C279/12 , C07C279/14 , C07D213/40 , C07D213/56 , C07D233/26 , C07D233/64 , C12N15/111 , C12N15/113 , C12N15/1131 , C12N15/1138 , C12N15/88 , C12N2310/14 , C12N2320/32 , Y10S514/943
摘要： This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

68. 发明申请

US20110033531A1 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof 审中-公开
标题翻译：第二代脂肪酸组合物，制剂及其使用和合成方法
公开(公告)号：US20110033531A1
公开(公告)日：2011-02-10
申请号：US12852620
申请日：2010-08-09
申请人： Steven C. Quay
发明人： Steven C. Quay
IPC分类号： A61K9/48 , A61K31/355 , A61P9/00 , A61P9/10 , A61P9/12 , A61P3/06
CPC分类号： A61K31/202 , A23L33/12 , A61K9/0053 , A61K9/145 , A61K9/146 , A61K9/4858 , A61K9/4866 , A61K31/16 , A61K31/164 , A61K31/353 , A61K31/355
摘要： An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.
摘要翻译：提供了用于治疗心血管疾病的口服给药脂肪酸组合物及其治疗方法。该化合物包括5Z，8Z，11Z，14Z，17Z-二十碳五烯酸乙醇酰胺（EPA乙醇酰胺），4Z，7Z，10Z，13Z，16Z，19Z-二十二碳六烯酸乙醇酰胺（DHA乙醇酰胺）和至少一种生育三烯酚。 EPA乙醇酰胺和DHA乙醇酰胺优选地每个剂型基本上在100-900mg的范围内。至少一种生育三烯酚基本上在每种剂型10-500mg的范围内。至少一种生育三烯酚包括α-生育三烯酚，生育三烯酚，γ-生育三烯酚或δ-生育三烯酚中的至少一种，优选基本上不含生育酚。组合物可以采取医疗食品或药物制剂的形式。组合物的优选制剂包括约525mg EPA乙醇酰胺，约315mg DHA乙醇酰胺和约50mgδ-生育三烯酚。 EPA和DHA乙醇酰胺可以由脂肪酸甘油三酯合成。

69. 发明授权

US07879349B2 Cyanocobalamin low viscosity aqueous formulations for intranasal delivery 有权
标题翻译：用于鼻内给药的氰钴胺素低粘度含水制剂
公开(公告)号：US07879349B2
公开(公告)日：2011-02-01
申请号：US12079875
申请日：2008-03-27
申请人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
发明人： Steven C. Quay , Peter C. Aprile , Zenaida O. Go , Anthony P. Sileno
IPC分类号： A61F13/00 , C07H23/00 , A61K31/70
CPC分类号： A61K9/0043 , A61K9/08 , A61K31/7056 , A61K31/714 , A61K47/10 , A61K47/12 , A61K47/186
摘要： A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.
摘要翻译：一种由氰钴胺素和水组成的稳定的药用无汞水溶液，其中所述氰钴胺溶液适合于鼻内给药，其粘度小于约1000cPs，其中所述氰钴胺溶液在鼻内给药时具有氰钴胺素的生物利用度相对于肌内注射氰钴胺素至少约7％，条件是溶液基本上不含汞和含汞化合物。本发明还涉及提高脑脊髓液（CSF）中维生素B12水平的方法，其包括向鼻内施用足够量的无汞氰钴胺溶液，以增加CSF中维生素B12的平均比例在血清（B12 CSF / B12血清×100）中至少约1.1，其包括鼻内施用氰钴胺水溶液，其中所述氰钴胺溶液相对于肌内注射氰钴胺素具有至少7％的生物利用度。

70. 发明申请

US20100112687A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING ERBB FAMILY GENE EXPRESSION AND USES THEREOF 审中-公开
标题翻译：用于抑制ERBB家族基因表达的核酸化合物及其用途
公开(公告)号：US20100112687A1
公开(公告)日：2010-05-06
申请号：US12528619
申请日：2008-02-28
申请人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
发明人： Steven C. Quay , James McSwiggen , Narendra K. Vaish , Mohammad Ahmadian
IPC分类号： C12N5/071 , C07H21/02
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/321 , C12N2310/3231 , C12N2310/3521
摘要： The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more ERBB family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more ERBB family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more ERBB family gene in a cell or in a subject to treat one or more ERBB family-related disease.
摘要翻译：本公开提供能够降低或沉默一种或多种ERBB家族基因表达的meroduplex核糖核酸分子（mdRNA）。本公开的mdRNA包含至少三条链，其结合形成由切口或间隙分开的至少两个不重叠的双链区域，其中一条链与一个或多个ERBB家族mRNA互补。此外，meroduplex可以具有至少一个被5-甲基尿苷取代的尿苷和任选的其它修饰或组合。还提供了降低细胞或受试者中一种或多种ERBB家族基因表达以治疗一种或多种ERBB家族相关疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式